Figure 5.
Differential sensitivity of SB28 and GL261 to double ICB. (A) Mice implanted intracranially with tumor were randomized into groups to receive intraperitoneal treatment with anti-PD-1 and anti-CTLA-4 antibodies, or isotype control, at the indicated doses and time-points. (B) Symptom-free survival of mice implanted with 1,600 SB28 glioma cells. (C) Symptom-free survival of mice implanted with 50,000 GL261 glioma cells. Survival curves represent accumulated data from two independent experiments (12 mice/group).